Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Vicore Pharma Holding AB ( (SE:VICO) ) just unveiled an announcement.
Vicore Pharma Holding AB announced its participation in the Jefferies Global Healthcare Conference in New York, where CEO Ahmed Mousa and VP of IR Megan Richards will present and hold meetings. This participation underscores Vicore’s strategic efforts to engage with stakeholders and highlight its advancements in drug development, potentially enhancing its industry positioning and investor relations.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a clinical-stage pharmaceutical company focused on developing a novel class of drugs, particularly angiotensin II type 2 receptor agonists (ATRAGs), for respiratory and fibrotic diseases like idiopathic pulmonary fibrosis (IPF). Their lead program, buloxibutid (C21), is an oral small molecule that has received Orphan Drug and Fast Track designation from the FDA and is under investigation in a Phase 2b trial.
Average Trading Volume: 356,459
Current Market Cap: SEK1.91B
Learn more about VICO stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue